29 results found.

Glioblastoma Clinical Trial using Selinexor

Karyopharm Therapeutics, Inc - Recruiting 18 years or older.
- A Phase II, Two-tier Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation Therapy and Temozolomide.
Selinexor

Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, G Clinical Trial using Bevacizumab; Rindopepimut (CDX-110) with GM-CSF; KLH

Celldex Therapeutics - Recruiting 18 years or older.
- A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma.
Bevacizumab; Rindopepimut (CDX-110) with GM-CSF; KLH

Brain Cancer Clinical Trial using Vorinostat; Bevacizumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma.
Vorinostat; Bevacizumab

Glioblastoma, or Recurrent Metastatic Cancer to the Brain Clinical Trial using ExAblate 4000

InSightec - Recruiting 18 years to 70 years.
- A Feasibility Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Lesions.
ExAblate 4000

Glioblastoma, Glioma Clinical Trial using GDC-0084

Genentech - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma.
GDC-0084

Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendrogliom Clinical Trial using Toca 511; 5-FC

Tocagen Inc. - Recruiting 18 years or older.
- A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma.
Toca 511; 5-FC

Recurrent Supratentorial Glioblastoma Multiforme, GBM, or Gliobla Clinical Trial using Live attenuated, oral (Sabin) serotype 1 poliovirus vaccine (PVSRIPO)

Duke University - Recruiting 18 years or older.
- Dose-finding and Safety Study of PVSRIPO Against Recurrent Glioblastoma.
Live attenuated, oral (Sabin) serotype 1 poliovirus vaccine (PVSRIPO)

Recurrent Glioblastoma Clinical Trial using Nivolumab; Ipilimumab; Bevacizumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Randomized Phase IIb, Open Label Study of Nivolumab or Nivolumab in Combination With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma (GBM).
Nivolumab; Ipilimumab; Bevacizumab

Glioblastoma Multiforme Clinical Trial using I-124-CLR1404

Cellectar Biosciences, Inc. - Recruiting 18 years or older.
- Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme.
I-124-CLR1404

Recurrent Glioblastoma, or Progressive Glioblastoma Clinical Trial using G-202

GenSpera, Inc. - Recruiting 18 years or older.
- An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients With Recurrent or Progressive Glioblastoma.
G-202

Glioma, Glioblastoma, or Brain Tumor, Recurrent Clinical Trial using ANG1005; Bevacizumab

Angiochem Inc - Recruiting 18 years or older.
- A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma.
ANG1005; Bevacizumab

Glioblastoma Clinical Trial using Blood draw - biomarkers; MRI-guided Laser Heat Ablation (MLA); Doxorubicin

Washington University School of Medicine - Recruiting 18 years or older.
- A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme.
Blood draw - biomarkers; MRI-guided Laser Heat Ablation (MLA); Doxorubicin

Recurrent Glioblastoma Clinical Trial using BGJ398

Novartis - Recruiting 18 years or older.
- A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma.
BGJ398

Advanced Malignant Glioma, Anaplastic Astrocytomas, or Glioblasto Clinical Trial using AMG 595

Amgen - Recruiting 18 years or older.
- A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).
AMG 595

Glioblastoma Multiforme, or Gliosarcoma Clinical Trial using AMG 102 with Avastin

Duke University - Recruiting 18 years or older.
- Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma.
AMG 102 with Avastin

Glioblastoma Multiforme Clinical Trial using TPI 287; Bevacizumab

Cortice Biosciences, Inc. - Recruiting 18 years or older.
- Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following Bevacizumab Alone.
TPI 287; Bevacizumab

Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma Clinical Trial using trebananib; placebo; bevacizumab; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma.
trebananib; placebo; bevacizumab; pharmacological study; laboratory biomarker analysis

Cancer Clinical Trial using Sativex

GW Pharmaceuticals Ltd. - Recruiting 18 years or older.
- A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma.
Sativex

Recurrent Glioblastoma Clinical Trial using MRI-PET; TMZ-PET

Massachusetts General Hospital - Recruiting 18 years or older.
- A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using [11C]Temozolomide PET and Vascular MRI.
MRI-PET; TMZ-PET

c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Delet Clinical Trial using INC280; Buparlisib

Novartis - Recruiting 18 years or older.
- A Phase Ib/II, Multi-center, Open-label Study of Single-agent INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma.
INC280; Buparlisib

Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligo Clinical Trial using Toca 511

Tocagen Inc. - Recruiting 18 years to 80 years.
- A P1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC.
Toca 511

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Na‹ve Patients With Recurrent Glioblastoma Multiforme.
anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study

Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood A Clinical Trial using oncolytic HSV-1716; dexamethasone; therapeutic conventional surgery; laboratory biomarker analysis

Pediatric Brain Tumor Consortium - Recruiting 16 years to 21 years.
- A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG).
oncolytic HSV-1716; dexamethasone; therapeutic conventional surgery; laboratory biomarker analysis

Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Clinical Trial using Temozolomide; hypofractionated radiation therapy; bevacizumab; questionnaire administration

Northwestern University - Recruiting 18 years or older.
- A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas.
Temozolomide; hypofractionated radiation therapy; bevacizumab; questionnaire administration

Recurrent Glioblastoma Clinical Trial using PF-299804 (Dacomitinib)

Grupo Espa¤ol de Investigaci¢n en Neurooncolog¡a - Recruiting 18 years or older.
- A Prospective Multicenter, Open Label, Phase II Pilot Clinical Trial to Evaluate Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation.
PF-299804 (Dacomitinib)

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using vorinostat; stereotactic body radiation therapy; laboratory biomarker analysis; pharmacological study; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- High-Dose Vorinostat With Radiation Therapy in the Treatment of Recurrent Glioma.
vorinostat; stereotactic body radiation therapy; laboratory biomarker analysis; pharmacological study; therapeutic conventional surgery

Glioblastoma Clinical Trial using Phase 1 Dose Escalation; Phase 1b; Ancillary Study

Actelion - Recruiting 18 years or older.
- A Phase 1/1b, Open-label Study in Patients With Recurrent Glioblastoma to Assess the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide.
Phase 1 Dose Escalation; Phase 1b; Ancillary Study

Recurrent Glioblastoma Clinical Trial using calorie-restricted ketogenic diet and transient fasting; standard nutrition

Johann Wolfgang Goethe University Hospitals - Recruiting 18 years or older.
- Calorie-restricted, Ketogenic Diet and Transient Fasting vs. Standard Nutrition During Reirradiation for Patients With Recurrent Glioblastoma: the ERGO2 Study.
calorie-restricted ketogenic diet and transient fasting; standard nutrition

Advanced Solid Tumors Clinical Trial using E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050

Eisai Inc. - Recruiting N/A or older.
- An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2).
E7050 plus E7080; E7080 plus E7050; E7050 plus E7080 or E7080 alone plus E7050 add-on therapy; E7050